Sugianli Adhi Kristianto, Ginting Franciscus, Kusumawati R Lia, Pranggono Emmy Hermiyati, Pasaribu Ayodhia Pitaloka, Gronthoud Firza, Geerlings Suzanne, Parwati Ida, De Jong Menno D, Van Leth Frank, Schultsz Constance
Department of Clinical Pathology, Faculty of Medicine, Universitas Padjadjaran, Dr Hasan Sadikin General Hospital Bandung, Bandung, Indonesia.
Department of Internal Medicine, Faculty of Medicine, Universitas Sumatera Utara, H. Adam Malik Hospital Medan, Medan, Indonesia.
J Antimicrob Chemother. 2017 May 1;72(5):1469-1477. doi: 10.1093/jac/dkw578.
Urinary tract infections (UTIs) are a common reason for empirical treatment with broad-spectrum antibiotics worldwide. However, population-based antimicrobial resistance (AMR) prevalence data to inform empirical treatment choice are lacking in many regions, because of limited surveillance capacity. We aimed to assess the prevalence of AMR to commonly used antimicrobial drugs in Escherichia coli and Klebsiella pneumoniae isolated from patients with community- or healthcare-associated UTIs on two islands of Indonesia.
We performed a cross-sectional patient-based study in public and private hospitals and clinics between April 2014 and May 2015. We screened patients for symptoms of UTIs and through urine dipstick analysis. Urine culture and susceptibility testing were supported by telemicrobiology and interactive virtual laboratory rounds. Surveillance data were entered in forms on mobile phones.
Of 3424 eligible patients, 3380 (98.7%) were included in the final analysis, and yielded 840 positive cultures and antimicrobial susceptibility data for 657 E. coli and K. pneumoniae isolates. Fosfomycin was the single oral treatment option with resistance prevalence <20% in both E. coli and K. pneumoniae in community settings. Tigecycline and fosfomycin were the only options for treatment of catheter-associated UTIs with resistance prevalence <20%, whilst the prevalence of resistance to meropenem was 21.3% in K. pneumoniae .
Patient-based surveillance of AMR in E. coli and K. pneumoniae causing UTIs indicates that resistance to the commonly available empirical treatment options is high in Indonesia. Smart AMR surveillance strategies are needed to inform policy makers and to guide interventions.
尿路感染(UTIs)是全球范围内使用广谱抗生素进行经验性治疗的常见原因。然而,由于监测能力有限,许多地区缺乏基于人群的抗菌药物耐药性(AMR)流行率数据来指导经验性治疗选择。我们旨在评估从印度尼西亚两个岛屿的社区或医疗保健相关尿路感染患者中分离出的大肠杆菌和肺炎克雷伯菌对常用抗菌药物的耐药率。
2014年4月至2015年5月期间,我们在公立和私立医院及诊所开展了一项基于患者的横断面研究。我们通过尿液试纸分析对患者进行尿路感染症状筛查。尿液培养和药敏试验由远程微生物学和交互式虚拟实验室会诊提供支持。监测数据通过手机录入表格。
在3424名符合条件的患者中,3380名(98.7%)纳入最终分析,共获得840份阳性培养物以及657株大肠杆菌和肺炎克雷伯菌分离株的抗菌药敏数据。在社区环境中,磷霉素是大肠杆菌和肺炎克雷伯菌耐药率均<20%的唯一口服治疗选择。替加环素和磷霉素是耐药率<20%的导管相关尿路感染的唯一治疗选择,而肺炎克雷伯菌对美罗培南的耐药率为21.3%。
对引起尿路感染的大肠杆菌和肺炎克雷伯菌进行基于患者的AMR监测表明,印度尼西亚对常用经验性治疗药物的耐药率很高。需要智能AMR监测策略来为政策制定者提供信息并指导干预措施。